Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 May 30;28(12):1680-9.
doi: 10.1002/sim.3578.

Using short-term response information to facilitate adaptive randomization for survival clinical trials

Affiliations

Using short-term response information to facilitate adaptive randomization for survival clinical trials

Xuelin Huang et al. Stat Med. .

Abstract

Increased survival is a common goal of cancer clinical trials. Owing to the long periods of observation and follow-up to assess patient survival outcome, it is difficult to use outcome-adaptive randomization in these trials. In practice, often information about a short-term response is quickly available during or shortly after treatment, and this short-term response is a good predictor for long-term survival. For example, complete remission of leukemia can be achieved and measured after a few cycles of treatment. It is a short-term response that is desirable for prolonging survival. We propose a new design for survival trials when such short-term response information is available. We use the short-term information to 'speed up' the adaptation of the randomization procedure. We establish a connection between the short-term response and the long-term survival through a Bayesian model, first by using prior clinical information, and then by dynamically updating the model according to information accumulated in the ongoing trial. Interim monitoring and final decision making are based upon inference on the primary outcome of survival. The new design uses fewer patients, and can more effectively assign patients to the better treatment arms. We demonstrate these properties through simulation studies.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery. 2004;3:711–715. - PubMed
    1. Pocock SJ. Group sequential methods in design and analysis of clinical trials. Biometrika. 1997;64:191–200.
    1. O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549–556. - PubMed
    1. Kim K, Demets DL. Design and analysis of group sequential tests based on the type I error spending rate function. Biometrika. 1987;74:149–154.
    1. Simon R. Optimal 2-stage designs for phase-II clinical trials. Controlled Clinical Trials. 1989;10:1–10. - PubMed

Publication types

LinkOut - more resources